Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as an oral tablet for oral use. It prevents malaria infection and treats acute uncomplicated malaria caused by Plasmodium falciparum in travelers and endemic‑region patients, including adults and children weighing at least 5 kg.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is used in the antimalarial drug class to prevent and treat malaria infections.

- Travel‑related malaria prophylaxis: provides protection for short‑term travelers to endemic areas. - Resident malaria prophylaxis: offers ongoing prevention for individuals living in malaria‑endemic regions. - Acute uncomplicated P. falciparum malaria treatment: clears parasitemia and resolves clinical symptoms.

Adverse reactions may occur with Malarone use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain or diarrhea: gastrointestinal disturbance.

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hematologic abnormalities: neutropenia or anemia. - Hypersensitivity reactions: rash, fever, or anaphylaxis.

Use Malarone with attention to specific safety considerations.

- Pregnancy: avoid unless benefits outweigh potential risks. - Breastfeeding: consider potential exposure to infant; use with caution. - Renal impairment: assess kidney function before initiating therapy. - Hepatic impairment: monitor liver function during treatment. - Adherence: ensure complete course to prevent resistance development. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Malarone may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations, compromising efficacy. - Antacids containing aluminum or magnesium: decrease atovaquone absorption.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase atovaquone levels, requiring observation. - Warfarin: potential alteration of INR, monitor coagulation status. - HIV protease inhibitors or azole antifungals: can increase atovaquone exposure, adjust therapy as needed. - Other antimalarials: concurrent use may enhance toxicity.